CeQur's $115 Million Series C5 Financing: A Major Bet on Simplifying Diabetes Management

The diabetes care landscape is shifting. CeQur just closed a $115 million Series C5 funding round—the largest ever raised by a European private medtech company—and it signals serious momentum in the wearable insulin-delivery market. The financing was led by heavyweight investors Credit Suisse Entrepreneur Capital and Endeavour Vision, with strong backing from Tandem Diabetes Care, Ypsomed Group, and several other prominent venture firms.

Why This Matters: The Problem CeQur Is Solving

Here’s the reality for millions of insulin-dependent diabetics: multiple daily injections are a burden. The numbers tell the story—nearly two-thirds of patients don’t feel comfortable injecting insulin publicly, creating a significant barrier to treatment adherence. Healthcare providers face their own challenge: getting patients to stick with complex injection regimens is one of the toughest aspects of diabetes management.

This friction translates to missed targets. Many patients on insulin therapy fail to achieve their glucose goals specifically because of the lifestyle restrictions and social stigma attached to frequent injections.

Meet CeQur Simplicity: The Answer

CeQur Simplicity is a three-day wearable patch designed to eliminate this friction. A single patch holds up to 200 units of rapid-acting insulin and replaces roughly nine mealtime injections over three days. It’s injection-free, discreet, and requires minimal user education—a direct response to the pain points patients and providers actually experience.

The clinical proof is compelling: 90% of patients using CeQur Simplicity reported better adherence compared to traditional multiple daily injections. The device is already FDA cleared and CE-marked, meaning it’s ready for real-world deployment.

The Market Opportunity Is Massive

Why are top-tier investors crowding into this round? The addressable market is estimated at $7.5 billion in the US alone—roughly double that globally. Over 3 million Americans currently rely on mealtime insulin injections, and many are underserved by existing options. This isn’t a niche play; it’s a fundamental redesign of how people manage insulin therapy.

What’s Next

CeQur plans to deploy these funds strategically: expanding manufacturing capacity, launching market development initiatives, and executing a phased commercial rollout beginning with a limited release in 2021. The company now has the capital and investor backing to scale aggressively.

CEO Bradley Paddock emphasized that pilot feedback from healthcare professionals, payers, and patients validates the device’s real-world value. With this firepower behind it, CeQur is positioned to reshape the insulin-delivery market for a massive patient population that’s been waiting for a simpler solution.